Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 5 | LM2222 | IM / UN |
Development of fatigue, joint pain, muscle pain, and muscle weakness as well as dysphagia. Rated her pain a 3-4 out of 10 on average. This was very atypical for her. Developed dysphagia and regurgitation
None
Migraine without aura
Daily multivitamin
None
Labs on 12/31/2024: Vitamin D 29, negative rheumatoid factor, CRP 0.45 anti-CCP negative ANA negative Lyme antibody negative every Kalosis antibody negative HIV negative uric acid 2.1, ferritin 500, hepatitis panel negative, ESR 20, magnesium normal, CK 1529, CMP with AST 105 otherwise within normal limits, CBC with WBC 3.1, percent monocytes 11.9 all others within normal limits. Labs obtained on 1/3/2025 with CK 1061, LDH 399, normal thyroid testing, normal phosphatase and magnesium, uric acid 1.8, AST 85. Labs on 1/9/2025: AST 68, CK8 115, myositis panel with NXP 2 antibodies elevated at 128. MRI of left lower leg on 1/1/2025 with acute nonspecific myositis consistent with history of rhabdo myelitis. EMG 1/13/2025 with severe myopathic EMG findings in proximal greater than distal muscles of the right upper extremity and right lower extremity consistent with myositis left quadricep biopsy on 1/31/2025 with mild type II myofiber atrophy and focal fiber type grouping consistent with reinnervation. Barium swallow study on 2/11/2025 essentially normal